A Systematic Review and Meta-Analysis of Human Milk Feeding and Morbidity in Very Low Birth Weight Infants.

Miller J, Tonkin E, Damarell RA, McPhee AJ, Suganuma M, Suganuma H, Middleton PF, Makrides M, Collins CT. · 2018

Read A Systematic Review and Meta-Analysis of Human Milk Feeding and Morbidity in Very Low Birth Weight Infants. by Miller J, Tonkin E, Damarell RA, McPhee AJ, Suganuma M, Suganuma H, Middleton PF, Makrides M, Collins CT. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6024377.txt.

Introduction

Miller and co-authors review how human milk affects illness in very low birth weight infants. Their systematic review and meta-analysis appeared in Nutrients. The infants were born at or before 28 weeks. Others weighed 1,500 grams or less at birth. Outcomes covered gut, eye, lung, and brain conditions.

The team pooled 49 studies published after 1990. Human milk clearly cut the risk of necrotising enterocolitis. Higher doses gave stronger protection. Any human milk beat exclusive preterm formula for that outcome. Milk also may have lowered late sepsis and severe eye disease. Evidence on pasteurisation stayed inconclusive. Readers get graded evidence for feeding choices in fragile newborns.

Catalog record

CREATORMiller J, Tonkin E, Damarell RA, McPhee AJ, Suganuma M, Suganuma H, Middleton PF, Makrides M, Collins CT.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE69 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6024377

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

A Systematic Review and Meta-Analysis of Human Milk Feeding and Morbidity in Very Low Birth Weight Infants By Jacqueline Miller, Emma Tonkin, Raechel A. Damarell, Andrew J. McPhee, Machiko Suganuma, Hiroki Suganuma, Philippa F. Middleton, Maria Makrides, Carmel T. Collins Published in: Nutrients DOI: 10.3390/nu10060707 ABSTRACT This systematic review and meta-analysis synthesised the post-1990 literature examining the effect of human milk on morbidity, specifically necrotising enterocolitis (NEC), late onset sepsis (LOS), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD) and neurodevelopment in infants born ≤28 weeks’ gestation and/or publications with reported infant mean birth weight of ≤1500 g. Online databases including Medline, PubMed, CINAHL, Scopus, and the Cochrane Central Register of Controlled Trials were searched, and comparisons were grouped as follows: exclusive human milk (EHM) versus exclusive preterm formula (EPTF), any human milk (HM) versus EPTF, higher versus lower dose HM, and unpasteurised versus pasteurised HM. Experimental and observational studies were pooled separately in meta-analyses. Risk of bias was assessed for each individual study and the GRADE system used to judge the certainty of the findings. Forty-nine studies (with 56 reports) were included, of which 44 could be included in meta-analyses. HM provided a clear protective effect against NEC, with an approximate 4% reduction in incidence. HM also provided a possible reduction in LOS, severe ROP and severe NEC. Particularly for NEC, any volume of HM is better than EPTF, and the higher the dose the greater the protection. Evidence regarding pasteurisation is inconclusive, but it appears to have no effect on some outcomes. Improving the intake of mother’s own milk (MOM) and/or donor HM results in small improvements in morbidity in this population. 1. INTRODUCTION Human milk (HM) is the feed of choice for preterm infants [1]. However, not all mothers can provide sufficient milk to meet requirements, and supplementation with either preterm formula (PTF) or donor human milk (DHM) is common practice. Current recommendations are for the use of mother’s own milk (MOM), when available, with appropriately screened and pasteurised DHM the next best choice if there is insufficient MOM [2,3]. Some countries, such as Norway, have largely used unpasteurised DHM, which may contribute to the protection DHM provides [4]. Previous randomised trials (RT) [5,6,7,8,9,10,11,12,13,14] and meta-analyses [15,16], provide evidence of the relative advantages of HM feeding compared with formula feeding. Advantages of HM feeding, with either pasteurised DHM or MOM, include protection from necrotising enterocolitis (NEC) [16,17] and infection [11,14] and improved cognitive outcomes, with very low birth weight (VLBW) infants having the greatest advantage [15]. However, much of this early research reflects feed compositions, clinical management and technology available in the 1980s and is now outdated. Advances in many non-nutrition related aspects of care, particularly the introduction of surfactant in the early 1990s represented a significant advance in the care of preterm infants with dramatic reduction in mortality and morbidity [18]. In addition, human milk banks, while common in some countries, are beginning to re-emerge in other countries, such as Australia, where access to DHM is limited and prioritised for the most vulnerable infants who stand to gain the most benefit. Currently in Australia there are now five milk banks in operation [19]. Therefore, an estimated 75% of Australian high risk preterm infants do not have access to pasteurised DHM. This systematic review summarises evidence on associations between different modes of feeding and morbidity. It aims to provide a direct comparison between exclusive human milk (EHM) and exclusive preterm formula (EPTF), to examine whether any HM was protective when infants also receive preterm formula and to explore the dose related effect of HM. As pasteurisation is known to destroy some of the immune-protective properties of HM [20,21,22] and unpasteurised MOM to provide antibodies specific to the mother–infant dyad [23], we also aimed to determine the effects of pasteurization of HM on infant morbidity. Is DHM important for the preterm infant whose mother provides enough breast milk to meet nearly all their requirements? Should it be limited to those who are unable to provide any HM? Is there a dose that achieves greatest clinical benefit? We therefore reviewed RTs and observational studies that examined the effect of HM on preterm infant morbidity. 2. METHODS 2.1. Registration The review is registered with PROSPERO International prospective register of systematic reviews and the protocol is available from [24]. 2.2. Eligibility Criteria 2.2.1. Types of Studies Experimental and observational studies, published from 1990 onwards, were considered for inclusion in this review. All component studies of relevant systematic reviews were also considered. 2.2.2. Types of Participants Infants born ≤28 weeks’ gestation (from 1990 onwards) and/or publications with reported study population mean birth weight of ≤1500 g were considered for inclusion. Post-discharge feeding studies were excluded. As quantifying the exposure (HM) was necessary to group studies, we excluded any studies where this could not be done reliably, e.g. where feeding intake data were reported retrospectively or measured at only one time point and extrapolated for the neonatal admission. 2.2.3. Types of Intervention Studies comparing the effects of HM were grouped according to the following exposure categories:EHM compared with EPTF—to provide a direct evaluation of the benefits of an exclusive HM diet.Any HM (includes EHM or HM plus preterm formula) compared with EPTF—to examine whether any HM was protective when infants also receive preterm formula.Dose related—exclusive or higher HM (higher dose HM plus preterm formula) intake compared with lower HM (lower dose HM plus preterm formula) intake. This comparison was included to explore the dose related effect of HM, i.e., is more HM beneficial when infants have at least some HM? No a priori categories were defined for “higher” or “lower” dose of HM. Therefore, studies included here may have compared EHM with mixed feeding groups, or alternatively all infant groups may have been mixed fed, with those having a higher proportion of enteral intake as HM compared with those having a lower proportion of enteral intake as HM.Unpasteurised HM compared with pasteurised HM (DHM and/or MOM). Pasteurisation is known to destroy some of the immune-protective properties of HM [20,21,22] and unpasteurised MOM provides antibodies specific to the mother–infant dyad [23]. Thus, this comparison was included to assess the effect of pasteurisation on the potential benefits of HM, and to attempt to differentiate the benefits associated with any HM, and those only associated with unpasteurised MOM. Studies reporting mixed feeding (HM plus PTF) were included if there was also a comparison between pasteurised and unpasteurised HM. 2.2.4. Type of Outcome Measures Outcomes included NEC (any and severe), late onset sepsis (LOS), bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP) (any and severe), and neurodevelopment, defined as cognitive or motor development. A holistic approach to inclusion was taken, therefore no single definition for each outcome was predetermined. Studies reporting composite outcomes (e.g., incidence of NEC and death) were excluded unless data were also provided for each outcome separately. 2.3. Information Sources and Study Selection Primary papers and systematic reviews were identified by searching databases including: Medline (Ovid), PubMed, CINAHL (EBSCOhost), Scopus, and the Cochrane Central Register of Controlled Trials (Wiley). All searches were conducted on 13 June 2017. Results were restricted to English language studies published from 1990. The search strategy incorporated and combined three key concepts:

Read the complete text